Women with rare diseases wait an average of 5.4 years for a diagnosis, compared to 3.7 years for men. Behind that gap lies a systemic pattern of dismissed symptoms, delayed referrals, and treatments optimized for male physiology. But a new generation of technologies — from AI-powered genomics to patient-driven data platforms — is beginning to close it. This article explores the scale of diagnostic gender bias in rare disease and the innovations poised to disrupt it.
The numbers are stark. Eighty percent of autoimmune disease patients are women, with lupus affecting women at a 9:1 ratio and Sjögren’s syndrome at 19:1. Yet a greater diagnostic delay in women than in men has been identified in at least 700 diseases. Women are directed to specialists later than men following symptom onset, and symptom management typically begins before diagnostic confirmation for men but only after confirmation for women — a pattern with real consequences for disease progression.
These delays are compounded by well-documented clinical bias. A 2018 review found that medical professionals are more likely to dismiss female patients as overly sensitive or as time-wasters. In cardiovascular care, women presenting with chest tightness are three times more likely to be prescribed anxiolytics than men with identical symptoms, who are more often referred onwards for evaluation.
The challenges extend well beyond diagnosis. As recently as 2019, women accounted for roughly 40% of participants in clinical trials for cancer, cardiovascular disease, and psychiatric disorders — despite representing 51% of the U.S. population. In rare disease research, where patient populations are already small, this underrepresentation makes it even harder to detect sex-specific treatment effects.
Women metabolize medications differently due to variations in body composition, hormone levels, and enzyme activity. Yet research on how hormonal fluctuations influence rare disease symptoms remains limited, and dedicated guidelines on sex-specific dosing are largely absent from clinical practice.
Encouragingly, a convergence of technologies is emerging to address these disparities.
In genomics, platforms like 3Billion are using deep learning and large-scale genomic databases to accelerate whole-exome and whole-genome sequencing interpretation, while Congetica‘s clinical decision support system automates next-generation sequencing analysis and can incorporate sex as an influencing variable — directly addressing a historic gap in genomic medicine. Face2Gene (FDNA), used by 70% of the world’s geneticists, applies AI-powered phenotyping to assist in syndrome prioritisation based on complex physiological data.
In digital health, wearables and remote monitoring tools can capture symptom patterns over time — particularly valuable for women whose symptoms are often dismissed during brief clinical encounters. Evidation Health, for instance, has leveraged wearables to generate real-world data for rare diseases including paroxysmal nocturnal hemoglobinuria.
Patient-driven platforms like PatientsLikeMe are also shifting the dynamic, enabling patients to track and share their experiences using clinically relevant measures. These longitudinal datasets are especially important for capturing women’s symptom profiles in contexts where they might otherwise be overlooked.
Meanwhile, AI-powered pharmacovigilance initiatives like AwareDX are using machine learning combined with pharmacogenomics to identify sex-specific adverse drug effects — a crucial step toward evidence-based, sex-stratified dosing guidelines.
On the policy front, the FDA’s 2025 draft guidance on sex differences in clinical evaluation and the EU’s EUGENMED-funded initiatives signal growing regulatory recognition that addressing these disparities requires coordinated, systemic action.
The technologies and companies profiled here represent just the beginning of what becomes possible when innovation is directed specifically toward health equity. As AI systems grow more sophisticated and patient advocacy becomes more data-driven, the diagnostic odyssey that has long defined women’s experience with rare diseases may finally become a more equitable journey. These challenges — from expanding women’s representation in clinical trials and AI-driven research to scaling personalised digital care — are central to the women’s health programme at HLTH USA 2026, which features dedicated sessions, investor discussions, and a pitch competition spotlighting the next generation of innovators working to close the gap.